5-Fluorouracil derivatives: a patent review

Expert Opinion on Therapeutic Patents
Pablo ÁlvarezAntonia Aranega

Abstract

The fluorinated analog of uracil 5-FU is an antimetabolite, active against a wide range of solid tumors. The main mechanism of action consists in interfering with DNA synthesis and mRNA translation. However, patients treated with 5-FU display several side effects, a result of its nonspecific cytotoxicity for tumor cells. Numerous modifications of the 5-FU structure have been performed in order to overcome these disadvantages. In this review, the metabolic pathways, pharmacokinetics and clinical pharmacology of 5-FU are briefly introduced. Moreover, several derivatives developed and patented, including oral 5-FU prodrugs and combinations with other active compounds, are presented. Finally, new innovative methods for administration and vehiculization of 5-FU and its derivatives are described. The search for less toxic 5-FU derivatives, which diminish or circumvent some of its disadvantages, has allowed the development of selective antitumor prodrugs and novel methods for tissue-specific drug delivery. Although some of these oral prodrugs are being used clinically, either alone or in combination therapy with other anticancer agents, it seems that the potential of personalized medicine, including pharmacogenomics and targeted thera...Continue Reading

References

Apr 1, 1989·Clinical Pharmacokinetics·R B Diasio, B E Harris
Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N PetrelliF M Muggia
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J J LokichJ G Fryer
Jan 1, 1988·Cancer Chemotherapy and Pharmacology·K OtaK Kimura
Feb 1, 1984·Chemical & Pharmaceutical Bulletin·S OzakiH Mori
Jan 1, 1981·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·J L Au, W Sadée
Feb 1, 1995·The Journal of Pharmacy and Pharmacology·M Boisdron-CelleJ P Benoit
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T R BurokerD H Gesme
Nov 10, 1998·Clinical and Experimental Pharmacology & Physiology·D M Thomas, J R Zalcberg
Jul 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J van GroeningenG Giaccone
Sep 23, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E TokunagaK Sugimachi
Apr 9, 2001·Investigational New Drugs·J S de Bono, C J Twelves
Apr 13, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H H BackusG J Peters
Jul 27, 2001·Current Pharmaceutical Biotechnology·F TanakaM Fukushima
Oct 11, 2001·British Journal of Cancer·M KawaharaUNKNOWN S-1 Cooperative Study Group (Lung Cancer Working Group)
Nov 29, 2001·The Journal of Biological Chemistry·Tadashi YoshiiAvraham Raz
Dec 4, 2001·Journal of the European Academy of Dermatology and Venereology : JEADV·J G Camarasa
Jun 27, 2002·Biochimica Et Biophysica Acta·G J PetersH M Pinedo
Nov 26, 2002·Clinical Colorectal Cancer·C EngR L Schilsky
Apr 8, 2003·Current Medicinal Chemistry. Anti-cancer Agents·M Malet-MartinoR Martino
May 2, 2003·Nature Reviews. Cancer·Daniel B LongleyPatrick G Johnston
Mar 30, 1957·Nature·C HEIDELBERGERJ SCHEINER
Dec 31, 2003·International Journal of Pharmaceutics·S Haznedar, B Dortunç
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Brian G CzitoHerbert I Hurwitz
Mar 6, 2004·Cancer Metastasis Reviews·James C Byrd, Robert S Bresalier
Apr 20, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·André B P van Kuilenburg
Apr 29, 2004·International Journal of Pharmaceutics·Anshul Gupte, Kadriye Ciftci
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tyvin A RichStephen T Mosley
Sep 9, 2004·Frontiers in Bioscience : a Journal and Virtual Library·Peter V Danenberg
Jun 2, 2005·Nature Reviews. Cancer·Samir D UndeviaMark J Ratain

❮ Previous
Next ❯

Citations

Aug 15, 2013·International Journal of Molecular Sciences·Yolande AsaraRoberto Madeddu
Aug 26, 2014·Drug Design, Development and Therapy·Veda PrachayasittikulVirapong Prachayasittikul
Apr 8, 2014·European Journal of Medicinal Chemistry·Esther CarrascoFernando Rodríguez-Serrano
Jul 15, 2015·Expert Opinion on Therapeutic Patents·Esmeralda CarrilloJuan Antonio Marchal
Sep 7, 2012·Expert Opinion on Drug Delivery·Beatriz Lasa-SaracibarMaría J Blanco-Prieto
Jan 12, 2016·Colloids and Surfaces. B, Biointerfaces·Manuela PetacciaGiovanna Mancini
Jan 15, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Long-Hao LiJi-Yan Liu
Jan 1, 2016·British Journal of Clinical Pharmacology·Ellen J B DerissenJos H Beijnen
Nov 25, 2014·Pharmaceutical Research·Chantal Al SabbaghElias Fattal
Feb 18, 2016·Bioorganic & Medicinal Chemistry Letters·Xuan XiaoChenzhong Liao
Nov 22, 2018·Journal of Drug Targeting·Giovanna LolloJean-Pierre Benoit
Aug 4, 2018·Current Drug Targets·Natalia Tołoczko-IwaniukWojciech Miltyk
Jun 18, 2019·Drug Metabolism Reviews·Himanshu VermaOm Silakari
Aug 15, 2018·International Journal of Oncology·Zexin WangQi Zhou
Sep 12, 2015·World Journal of Gastroenterology : WJG·Yu YanRui-Fen Wang
Jun 14, 2019·Frontiers in Microbiology·Jessica M Thomson, Iain L Lamont
Jan 9, 2014·Bioorganicheskaia khimiia·A V SemakovIu G Molotkovskiĭ
Nov 5, 2019·The Journal of Dermatological Treatment·Abeer Abd Elhakam HodeibRaghda Ahmed Zaki Talaat
Feb 6, 2016·Molecular Medicine Reports·Junhua XiaoPing Zheng
Sep 5, 2019·Biochemical and Biophysical Research Communications·Yen-Hua HuangCheng-Yang Huang
Dec 5, 2020·Bioorganic & Medicinal Chemistry·Manuela PetacciaGiovanna Mancini
Mar 2, 2021·Frontiers in Cell and Developmental Biology·Chengyi MaoYong Yuan
Oct 17, 2020·Clinical Pharmacokinetics·Ellen J B Derissen, Jos H Beijnen
Apr 20, 2019·Journal of Medicinal Chemistry·Ran ZhangJing-Yuan Xu
Apr 26, 2018·ACS Omega·Yi-Gui Wang, Ericka C Barnes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.